Leukemia & lymphoma · 2021
Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cao Xin-Xin, Yi Shu-Hua, Jiang Zhong-Xing, He Jing-Song, Yang Wei, Du Juan, Sun Chun-Yan, Wu Yu, Chen Wen-Ming, Liu Xiao-Jun, Li Bing-Zong, Li Chun-Rui, Sang Wei, Liu Qin-Hua, Chu Xiao-Xia, Li Fei, Bai Ou, Mao Min, Fu Rong, Wang Wei, Liu Li-Hong, Wang Lu-Qun, Dong Yu-Jun, Luo Jun, Li Zhen-Ling, Wei Yong-Qiang, Zhang Qi-Ke, Liu Jing, Ding Kai-Yang, Zou Liang, Chen Bi-Yun, Hua Luo-Ming, Jing Hong-Mei, He Juan, Wang Liang, Li Jian, Qiu Lu-Gui
Аннотация
In this study, we aimed to investigate treatment options and the prognosis of patients with WM in China. This retrospective study included 1141 patients diagnosed with symptomatic WM between January 2003 and December 2019 at 35 tertiary hospitals in 22 provinces of China. Fifty-four patients (7.3%) received monotherapy, 264 (36.0%) received chemoimmunotherapy, 395 (53.8%) received other combination regimens without rituximab, and 21 (2.9%) received ibrutinib. Using a multivariable Cox regression model, age > 65 years old, platelets <100 × 109/L, serum albumin <3.5 g/dl, β2 microglobulin concentration ≥4 mg/L and LDH ≥250 IU/L predicted poor OS. In summary, our study showed that frontline treatment choices for WM are widely heterogeneous. We validated most of the established prognostic factors in the rIPSS (age >65 years, LDH ≥250 IU/L, ALB <3.5 g/dl and β2 microglobulin ≥4 mg/L) together with PLT ≤ 100 × 109/L indicate a poor prognosis for patients with WM.